VKTX Advances Weight-Loss Drug
Viking Therapeutics initiates Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist for weight loss
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
VKTX Initiates Phase 1 Study
Viking Therapeutics initiates Phase 1 study to evaluate novel amylin receptor agonist VK3019 in healthy adults